Here are the DEF 14A proxy statements from InfuSystem Holdings, Inc. (INFU) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow INFU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INFU filings page.
InfuSystem Holdings, Inc. is asking shareholders to approve seven director nominees, an advisory vote on executive pay, an increase to its 2021 Equity Incentive Plan share pool, and ratification of Grant Thornton as auditor at a fully virtual May 11, 2026 annual meeting.
The proxy highlights a strong 2025, with record revenue of $143.4 million, up 6%, net income of $6.6 million, up 183%, and record Adjusted EBITDA of $31.5 million with a 21.9% margin. Operating cash flow rose to $24.4 million, while capital spending fell by more than 50%, net debt dropped 30% to $16.4 million, and the company repurchased 1.3 million shares for $9.9 million.
Management describes a shift toward less capital‑intensive growth, led by rapid expansion in wound care and continued oncology strength, and notes a 2026 restructuring of its largest biomedical services contract that will reduce annual revenue by $7.1 million but is expected to improve earnings and cash flow. The board seeks to add 1,000,000 shares to the 2021 Equity Incentive Plan, bringing the reserve to 7,000,000 shares, to continue using equity awards as a key part of executive and director compensation.